Aktie 688176 JIANGSU YAHONG MEDITECH CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Jiangsu Yahong Meditech Co., Ltd.

Aktien

688176

CNE100005XW0

688176

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 24.05.2024 		% 5 Tage % 1. Jan.
5.95 CNY -3.41% Intraday Chart für Jiangsu Yahong Meditech Co., Ltd. -6.74% -44.81%
29.04. Jiangsu Yahong Meditech Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
19.03. Asieris Pharmaceuticals gibt positive Ergebnisse der multizentrischen globalen klinischen Phase-III-Studie bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.
Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN
Jiangsu Yahong Meditech to Buy Back Shares for Up to 100 Million Yuan
Jiangsu Yahong Meditech Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
Jiangsu Yahong Meditech Co., Ltd. authorizes a Buyback Plan.
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU
Asieris Pharmaceuticals Announces Set-Up of the Women's Health Business Unit for Commercialization
Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit
Certain A Shares of Jiangsu Yahong Meditech Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-JAN-2024.
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China
Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting
Jiangsu Yahong Meditech Completes Phase III Trial Into APL1702 Drug; Shares Drop 4%
Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint
Jiangsu Yahong Meditech Co., Ltd.(XSSC:688176) added to S&P Global BMI Index
Jiangsu Yahong Meditech Enrolls First Subjects for Ulcerative Colitis Drug Trial
Jiangsu Yahong Meditech Gets Nod to Trial Ulcerative Colitis Drug
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 688176 Aktie
  4. Nachrichten Jiangsu Yahong Meditech Co., Ltd.
  5. Andere Sprachen